Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bradford Graves

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Current Topics in Medicinal Chemistry|April 28, 2005
Small molecule inhibitors of p53/MDM2 interactionNader Fotouhi, Bradford Graves
Methods in Enzymology|December 13, 2005
Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspectsDavid C Fry, Bradford Graves, Lyubomir T Vassilev
Molecular Cell|March 31, 2019
Distinct USP25 and USP28 Oligomerization States Regulate Deubiquitinating ActivityMalte Gersch, Jane L Wagstaff, Angela V Toms, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitorDavid C Fry, Charles Wartchow, Bradford Graves, et al.
Science (New York, N.Y.)|January 6, 2004
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2Lyubomir T Vassilev, Binh T Vu, Bradford Graves, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical DevelopmentBinh Vu, Peter Wovkulich, Giacomo Pizzolato, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 30, 2012
Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerizationBradford Graves, Thelma Thompson, Mingxuan Xia, et al.
Cancer Research|February 13, 2013
MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer modelsChristian Tovar, Bradford Graves, Kathryn Packman, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical DevelopmentZhuming Zhang, Xin-Jie Chu, Jin-Jun Liu, et al.
Bioorganic & Medicinal Chemistry|July 7, 2014
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapyZhuming Zhang, Qingjie Ding, Jin-Jun Liu, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Current Topics in Medicinal Chemistry|April 28, 2005
Small molecule inhibitors of p53/MDM2 interactionNader Fotouhi, Bradford Graves
Methods in Enzymology|December 13, 2005
Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspectsDavid C Fry, Bradford Graves, Lyubomir T Vassilev
Molecular Cell|March 31, 2019
Distinct USP25 and USP28 Oligomerization States Regulate Deubiquitinating ActivityMalte Gersch, Jane L Wagstaff, Angela V Toms, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitorDavid C Fry, Charles Wartchow, Bradford Graves, et al.
Science (New York, N.Y.)|January 6, 2004
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2Lyubomir T Vassilev, Binh T Vu, Bradford Graves, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical DevelopmentBinh Vu, Peter Wovkulich, Giacomo Pizzolato, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 30, 2012
Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerizationBradford Graves, Thelma Thompson, Mingxuan Xia, et al.
Cancer Research|February 13, 2013
MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer modelsChristian Tovar, Bradford Graves, Kathryn Packman, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical DevelopmentZhuming Zhang, Xin-Jie Chu, Jin-Jun Liu, et al.
Bioorganic & Medicinal Chemistry|July 7, 2014
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapyZhuming Zhang, Qingjie Ding, Jin-Jun Liu, et al.
Pageof 2